Omega Diagnostics Group Plc Company Profile (LON:ODX)

About Omega Diagnostics Group Plc (LON:ODX)

Omega Diagnostics Group Plc logoOmega Diagnostics Group PLC is a medical diagnostics company. The Company's segments are Allergy and Autoimmune; Food Intolerance; Infectious/Other, and Corporate. Its product categories include allergy, anemia, autoimmunity, fertility and growth hormones, food intolerance, infectious disease, inflammation, quality control, thyroid hormones and tumor markers. For allergy, it offers Allergodip, which is an enzyme immunoassay for the semi-quantitative determination of Specific immunoglobulin E (IgE) in serum or plasma. For anemia, it offers ATHOZYME Ferritin, which is an enzyme-immunoassay (ELISA) test for the detection and quantification of Ferritin in human serum. It offers a range of products for Rheumatoid Arthritis, Systemic Lupus Erythematosus (SLE), Antiphospholipid Syndrome (APS), Connective Tissue Disease, Gastrointestinal, and Vasculitis and Renal Disease. Its Fertility Hormones products include PATHOZYME-LH (Luteinizing Hormone), PATHOZYME-Prolactin and PATHOZYME-Oestradiol.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Diagnostic & Testing Substances
  • Sub-Industry: N/A
  • Symbol: LON:ODX
  • CUSIP: N/A
  • Web: www.omegadiagnostics.com/
Capitalization:
  • Market Cap: £23.65 million
  • Outstanding Shares: 108,745,000
Average Prices:
  • 50 Day Moving Avg: GBX 22.54
  • 200 Day Moving Avg: GBX 21.89
  • 52 Week Range: GBX 15.94 - GBX 28.01
P/E:
  • Trailing P/E Ratio: 31.33
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: £14.25 million
  • Price / Sales: 1.66
  • Book Value: GBX 0.20 per share
  • Price / Book: 1.09
Profitability:
  • EBITDA: £1.29 million
  • Net Margins: 4.46%
  • Return on Equity: 3.10%
  • Return on Assets: 2.60%
Misc:
  • Average Volume: 94,354 shs.
 

Frequently Asked Questions for Omega Diagnostics Group Plc (LON:ODX)

What is Omega Diagnostics Group Plc's stock symbol?

Omega Diagnostics Group Plc trades on the London Stock Exchange (LON) under the ticker symbol "ODX."

Where is Omega Diagnostics Group Plc's stock going? Where will Omega Diagnostics Group Plc's stock price be in 2017?

0 brokers have issued 1-year target prices for Omega Diagnostics Group Plc's shares. Their forecasts range from GBX 30 to GBX 30. On average, they expect Omega Diagnostics Group Plc's share price to reach GBX 30 in the next year. View Analyst Ratings for Omega Diagnostics Group Plc.

Who are some of Omega Diagnostics Group Plc's key competitors?

Who are Omega Diagnostics Group Plc's key executives?

Omega Diagnostics Group Plc's management team includes the folowing people:

  • Andrew Shepherd, Chief Executive, Managing Director, Executive Director
  • Kieron Harbinson, Group Finance Director, Company Secretary, Executive Director
  • Colin King, Chief Operating Officer, Director
  • Iain Logan, Group Financial Controller
  • Jag Grewal, Group Sales and Marketing Director, Executive Director
  • Karsten Brenzke, Site Manager of Omega Diagnostics GmbH
  • Mike Gordon, Group Operations Director
  • Prashant Maniar, Managing Director of Omega Dx (Asia) Pvt Limited
  • Edward Valente, Group Research and Development Director
  • Jamie Yexley, Site Manager of Genesis Diagnostics Limited and Cambridge Nutritional Sciences Limited

How do I buy Omega Diagnostics Group Plc stock?

Shares of Omega Diagnostics Group Plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Omega Diagnostics Group Plc's stock price today?

One share of Omega Diagnostics Group Plc stock can currently be purchased for approximately GBX 21.75.


MarketBeat Community Rating for Omega Diagnostics Group Plc (LON ODX)
Community Ranking:  0.8 out of 5 ()
Outperform Votes:  24 (Vote Outperform)
Underperform Votes:  122 (Vote Underperform)
Total Votes:  146
MarketBeat's community ratings are surveys of what our community members think about Omega Diagnostics Group Plc and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Omega Diagnostics Group Plc (LON:ODX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: GBX 30
Consensus Price Target History for Omega Diagnostics Group Plc (LON:ODX)
Price Target History for Omega Diagnostics Group Plc (LON:ODX)
Analysts' Ratings History for Omega Diagnostics Group Plc (LON:ODX)
Show:
DateFirmActionRatingPrice TargetDetails
10/16/2017FinnCapReiterated RatingCorporateGBX 30View Rating Details
(Data available from 10/20/2015 forward)

Earnings

Earnings History for Omega Diagnostics Group Plc (LON:ODX)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Omega Diagnostics Group Plc (LON:ODX)
Current Year EPS Consensus Estimate: $0.84 EPS

Dividends

Dividend History for Omega Diagnostics Group Plc (LON:ODX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Omega Diagnostics Group Plc (LON:ODX)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Omega Diagnostics Group Plc (LON:ODX)
Latest Headlines for Omega Diagnostics Group Plc (LON:ODX)
Source:

Social

Social activity is not available for this stock.

Chart

Omega Diagnostics Group Plc (ODX) Chart for Friday, October, 20, 2017

This page was last updated on 10/20/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.